Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis

Peggy P. Ho,Lawrence Steinman
DOI: https://doi.org/10.1073/pnas.1524890113
IF: 11.1
2016-01-25
Proceedings of the National Academy of Sciences
Abstract:Significance Bile acids bind to the nuclear hormone receptor, farnesoid X receptor (FXR). This bile acid–FXR interaction regulates bile acid synthesis, transport, and cholesterol metabolism. Recently, drugs targeting FXR activation have been reported to treat both liver and intestinal inflammatory diseases in both animal models and human clinical trials. Experimental autoimmune encephalomyelitis (EAE) is an inflammatory demyelinating disease of the central nervous system and serves as an animal model for multiple sclerosis (MS). In this study, we found that FXR knockout mice had more severe EAE, and treatment of mice with established EAE with a synthetic FXR agonist, obeticholic acid (6α-ethyl-chenodeoxycholic acid, 6-ECDCA), reduced EAE severity. Thus, we provide an FXR target for development of a previously unidentified disease-modifying therapy for MS.
What problem does this paper attempt to address?